GlassScriptPhysician profile
Daniel Aaron Brody
NPI 1013371731
$14,110.26
in general payments reported to CMS, 2019-2025
68 companies · $2,579 in 2025
The $2,579 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $1,806 · 2021: $2,053 · 2022: $2,290 · 2023: $2,085 · 2024: $2,939 · 2025: $2,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,602.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,894.26 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,607.17 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,107.38 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,092.38 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,018.04 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.12 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $548.49 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $459.38 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.63 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Amgen INC. | $381.19 | 2020-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $333.96 | 2023-2025 | Rexulti, Vyepti |
| Janssen Pharmaceuticals, INC | $293.91 | 2021-2025 | Spravato |
| Esperion Therapeutics, INC. | $256.97 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $242.09 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $227.92 | 2020-2025 | Verquvo, Capvaxive, Gardasil 9 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $209.41 | 2025 | Barostim Neo System |
| Idorsia Pharmaceuticals US INC | $189.68 | 2022-2025 | Quviviq, Quviviq |
| Sanofi-Aventis U.S. LLC | $185.91 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.83 | 2020-2023 | Trintellix |
| Exact Sciences Corporation | $155.88 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $150.74 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $146.46 | 2021-2024 | Strensiq |
| Avanos Medical | $142.24 | 2022 | |
| Antares Pharma, INC. | $140.16 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $131.75 | 2023-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $120.45 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $113.08 | 2020-2022 | |
| Daiichi Sankyo INC. | $111.19 | 2019-2020 | |
| Bausch Health US, LLC | $94.32 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $93.90 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $91.84 | 2024-2025 | Gemtesa |
| Gilead Sciences, INC. | $91.13 | 2019 | |
| Radius Health, INC. | $90.06 | 2025 | Tymlos |
| Upsher-Smith Laboratories LLC | $87.02 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.37 | 2022 | |
| Amarin Pharma, INC. | $68.67 | 2020-2021 | |
| Axsome Therapeutics, INC. | $65.89 | 2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $60.55 | 2022-2023 | Myrbetriq |
| Mannkind Corporation | $56.26 | 2022 | |
| Allergan, INC. | $56.13 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.38 | 2024-2025 | Caplyta |
| Eisai INC. | $50.96 | 2020-2021 | |
| Abiomed | $49.43 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $46.58 | 2023 | Opsumit, Uptravi |
| Pulmonx Corporation | $45.11 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Currax Pharmaceuticals LLC | $41.84 | 2020-2023 | Nexletol, Nexlizet, Contrave |
| Teva Pharmaceuticals USA, INC. | $40.34 | 2020-2025 | Austedo Xr |
| Abbott Laboratories | $37.29 | 2022-2023 | Proclaim |
| Insulet Corporation | $36.39 | 2025 | Omnipod |
| Medtronic, INC. | $35.50 | 2024-2025 | Interstim |
| Madrigal Pharmaceuticals | $33.69 | 2025 | Rezdiffra |
| Vbi Vaccine (Delaware) INC. | $31.62 | 2022 | |
| Ibsa Pharma INC. | $24.97 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $24.31 | 2023 | |
| Halozyme INC | $23.17 | 2023 | |
| Jazz Pharmaceuticals INC. | $22.61 | 2021 | |
| Neos Therapeutics, LP | $20.39 | 2021 | |
| Amag Pharmaceuticals, INC. | $20.38 | 2019 | |
| Shield Therapeutics INC | $19.94 | 2025 | |
| Redhill Biopharma INC. | $17.93 | 2020 | |
| Aimmune Therapeutics, INC. | $16.68 | 2024 | |
| Inspire Medical Systems, INC. | $16.45 | 2025 | Inspire |
| Hikma Pharmaceuticals USA | $15.55 | 2023 | Kloxxado, Mitigare, Ryaltris |
| Dermira, INC. | $13.17 | 2020 | |
| Clarus Therapeutics INC. | $13.03 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.91 | 2022 | Xyosted, Tlando |
| Evofem Biosciences, INC. | $12.52 | 2021 | |
| Linus Health, INC. | $10.31 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.